EVERGRAF 0.5MG EVERGRAF 0.5MG belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). EVERGRAF 0.5MG is an immunosuppressive macrolide. USED FOR Breast cancer the patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. EVERGRAF 0.5MG is used in an advanced stage of breast cancer. Neuroendocrine tumors EVERGRAF 0.5MG involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer patient treating with EVERGRAF 0.5MG after the failure of treatment with Sunitinib or Sorafenib. EVERGRAF 0.5MG also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Evergraf is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Evergraf bind with intercellular protein (FKBP-12), leads to in...